A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 485 participants.
Also called NCT06269107
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 485 participants
- Sponsor
- Registry
-
NCT06269107
-
- Other papers using this trial's data
- Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, China, Greece, India, Italy, Japan, Poland, Puerto Rico, South Africa, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT06269107. Randomized; no masking; primary purpose treatment. Start 2024-02-15 (actual); primary completion 2025-05-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- Acronym
- COMBINE 4
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- IcoSema
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06269107- Content hash
81790d02273d5ef84920c17486c98c12da99b9024e4d7a6e3012e01d33cb574c